Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

0.5906 -0.0021 (-0.35%)
Streaming Delayed Price Updated: 3:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aprea Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday? ↗
FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Inc. (NASDAQ: APRE) Making Surprising Moves in Thursday Session
Via Investor Brand Network
News headline image
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor) 
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
News headline image
A Look Into Healthcare Sector Value Stocks ↗
 
Via Benzinga
News headline image
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ET 
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
From Aprea Therapeutics
Via GlobeNewswire
News headline image
5 Value Stocks To Watch In The Healthcare Sector ↗
 
Via Benzinga
News headline image
5 Value Stocks To Watch In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying ↗
The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
News headline image
Aprea Therapeutics to Present at BIO International Convention
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
From Aprea Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 76 companies set new 52-week lows. 
Via Benzinga
News headline image
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023 ↗
 
Via Benzinga
News headline image
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Aprea Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.